Abstract

In the current clinical trials,observed treatment on recrudescent and metastatic breast cancer which can be anthracycline-resistant and taxane-resistant with Ixabepilone、Larotaxel and their combination;and treating climacteric-positive and tamoxifen-resistant advanced breast cancer with steroid sulfatase inhibitor STX64 or combination of exemestane and celecoxib;Treating chemotherapy-refractory HER2-positive metastatic breast cancer with lapatinib and pemetrexed as well as their combination.Results have demonstrated superior efficacy and safety,and some of which are worthy of further observation. Key words: Breast neoplasms; Drug therapy

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call